FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2618764609> ?p ?o ?g. }

• W2618764609 endingPage "102639" @default.
• W2618764609 startingPage "102617" @default.
• W2618764609 abstract "// Christos Fountzilas 1 , Sukeshi Patel 1 and Devalingam Mahalingam 1 1 The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA Correspondence to: Devalingam Mahalingam, email: Mahalingam@uthscsa.edu Keywords: oncolytic virus, immunotherapy, cytotoxicity Received: April 19, 2017      Accepted: May 03, 2017      Published: May 31, 2017 ABSTRACT Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare their normal counterparts. OVs can access cells through binding to receptors on their surface or through fusion with the plasma membrane and establish a lytic cycle in tumors, while leaving normal tissue essentially unharmed. Multiple viruses have been investigated in humans for the past century. IMLYGIC™ (T-VEC/Talimogene Laherparepvec), a genetically engineered Herpes Simplex Virus, is the first OV approved for use in the United States and the European Union for patients with locally advanced or non-resectable melanoma. Although OVs have a favorable toxicity profile and are impressively active anticancer agents in vitro and in vivo the majority of OVs have limited clinical efficacy as a single agent. While a virus-induced antitumor immune response can enhance oncolysis, when OVs are used systemically, the antiviral immune response can prevent the virus reaching the tumor tissue and having a therapeutic effect. Intratumoral administration can provide direct access to tumor tissue and be beneficial in reducing side effects. Immune checkpoint stimulation in tumor tissue has been noted after OV therapy and can be a natural response to viral-induced oncolysis. Also for immune checkpoint inhibition to be effective in treating cancer, an immune response to tumor neoantigens and an inflamed tumor microenvironment are required, both of which treatment with an OV may provide. Therefore, direct and indirect mechanisms of tumor killing provide rationale for clinical trials investigating the combination of OVs other forms of cancer therapy, including immune checkpoint inhibition." @default.
• W2618764609 created "2017-06-05" @default.
• W2618764609 creator A5004814161 @default.
• W2618764609 creator A5033837903 @default.
• W2618764609 creator A5056309801 @default.
• W2618764609 date "2017-05-31" @default.
• W2618764609 modified "2023-09-30" @default.
• W2618764609 title "Review: Oncolytic virotherapy, updates and future directions" @default.
• W2618764609 cites W1493283693 @default.
• W2618764609 cites W149654997 @default.
• W2618764609 cites W1512409450 @default.
• W2618764609 cites W1578418351 @default.
• W2618764609 cites W1582164157 @default.
• W2618764609 cites W1583371546 @default.
• W2618764609 cites W1590408437 @default.
• W2618764609 cites W1591890160 @default.
• W2618764609 cites W1665842545 @default.
• W2618764609 cites W1675112595 @default.
• W2618764609 cites W1730695993 @default.
• W2618764609 cites W1768741830 @default.
• W2618764609 cites W17775240 @default.
• W2618764609 cites W1827720726 @default.
• W2618764609 cites W1845094941 @default.
• W2618764609 cites W1858541575 @default.
• W2618764609 cites W1903745386 @default.
• W2618764609 cites W1928896893 @default.
• W2618764609 cites W1936207051 @default.
• W2618764609 cites W1963549136 @default.
• W2618764609 cites W1965497380 @default.
• W2618764609 cites W1966151215 @default.
• W2618764609 cites W1966766953 @default.
• W2618764609 cites W1970212185 @default.
• W2618764609 cites W1970368422 @default.
• W2618764609 cites W1971042261 @default.
• W2618764609 cites W1971056267 @default.
• W2618764609 cites W1971532562 @default.
• W2618764609 cites W1972455109 @default.
• W2618764609 cites W1974638172 @default.
• W2618764609 cites W1975051039 @default.
• W2618764609 cites W1978246274 @default.
• W2618764609 cites W1978558644 @default.
• W2618764609 cites W1979127187 @default.
• W2618764609 cites W1979702687 @default.
• W2618764609 cites W1980477679 @default.
• W2618764609 cites W1981400752 @default.
• W2618764609 cites W1981665941 @default.
• W2618764609 cites W1983813078 @default.
• W2618764609 cites W1986462840 @default.
• W2618764609 cites W1987741335 @default.
• W2618764609 cites W1989215766 @default.
• W2618764609 cites W1992543351 @default.
• W2618764609 cites W1993103946 @default.
• W2618764609 cites W1993835312 @default.
• W2618764609 cites W1996996990 @default.
• W2618764609 cites W1998933123 @default.
• W2618764609 cites W1999009503 @default.
• W2618764609 cites W1999325713 @default.
• W2618764609 cites W2001566086 @default.
• W2618764609 cites W2001786959 @default.
• W2618764609 cites W2002230655 @default.
• W2618764609 cites W2002589386 @default.
• W2618764609 cites W2002726776 @default.
• W2618764609 cites W2002924921 @default.
• W2618764609 cites W2003012076 @default.
• W2618764609 cites W2003781492 @default.
• W2618764609 cites W2004100752 @default.
• W2618764609 cites W2010822166 @default.
• W2618764609 cites W2011195144 @default.
• W2618764609 cites W2012150814 @default.
• W2618764609 cites W2012611138 @default.
• W2618764609 cites W2013818959 @default.
• W2618764609 cites W2015148142 @default.
• W2618764609 cites W2015426350 @default.
• W2618764609 cites W2016356714 @default.
• W2618764609 cites W2017980124 @default.
• W2618764609 cites W2018106813 @default.
• W2618764609 cites W2018535642 @default.
• W2618764609 cites W2019410232 @default.
• W2618764609 cites W2019607817 @default.
• W2618764609 cites W2020743119 @default.
• W2618764609 cites W2022299158 @default.
• W2618764609 cites W2023088570 @default.
• W2618764609 cites W2023818726 @default.
• W2618764609 cites W2024797655 @default.
• W2618764609 cites W2025064244 @default.
• W2618764609 cites W2025359710 @default.
• W2618764609 cites W2026136467 @default.
• W2618764609 cites W2026275021 @default.
• W2618764609 cites W2026793574 @default.
• W2618764609 cites W2026824776 @default.
• W2618764609 cites W2027178820 @default.
• W2618764609 cites W2028577286 @default.
• W2618764609 cites W2029325618 @default.
• W2618764609 cites W2029647918 @default.
• W2618764609 cites W2029739739 @default.
• W2618764609 cites W2032014779 @default.
• W2618764609 cites W2032496897 @default.
• W2618764609 cites W2035290900 @default.

• next